Analytical characterization of NOTA-modified somatropins

Journal of Pharmaceutical and Biomedical Analysis

Volumn 96, Issue , 2014, Pages 1-9

  Bracke, Nathalie ^a   Wynendaele, Evelien ^a   D'Hondt, Matthias ^a   Haselberg, Rob ^b   Somsen, Govert W ^b   Pauwels, Ewald ^a   Van de Wiele, Christoph ^c   De Spiegeleer, Bart ^a  

^a GHENT UNIVERSITY   (Belgium)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

CE MS; LC MS; NOTA modification; Peptide mapping; Somatropin

Indexed keywords

2 (4 ISOTHIOCYANATOBENZYL) 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID; CHELATING AGENT; CHYMOTRYPSIN; GALLIUM; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE; LYSINE; LYSINE 140; LYSINE 158; LYSINE 172; LYSINE 70; RADIOPHARMACEUTICAL AGENT; TRYPSIN; UNCLASSIFIED DRUG; 1,4,7-TRIAZACYCLONONANE-N,N',N''-TRIACETIC ACID; 2-(4-ISOTHIOCYANATOBENZYL)-1,4,7-TRIAZACYCLONONANE-1,4,7-TRIACETIC ACID; HETEROCYCLIC COMPOUND; ISOTHIOCYANIC ACID DERIVATIVE;

ANALYTIC METHOD; ARTICLE; BINDING SITE; BIOLOGICAL ACTIVITY; CANCER THERAPY; CHELATION; CHEMICAL ANALYSIS; CHEMICAL MODIFICATION; COMPLEX FORMATION; COMPUTER MODEL; CRYSTAL STRUCTURE; DRUG IDENTIFICATION; DRUG SYNTHESIS; HUMAN; MASS SPECTROMETRY; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR BINDING; CHEMISTRY; COMPUTER SIMULATION; CRYSTALLIZATION; PH; PROCEDURES; SYNTHESIS;

CHELATING AGENTS; COMPUTER SIMULATION; CRYSTALLIZATION; HETEROCYCLIC COMPOUNDS; HUMAN GROWTH HORMONE; HYDROGEN-ION CONCENTRATION; ISOTHIOCYANATES; PEPTIDE MAPPING; RADIOPHARMACEUTICALS;

EID: 84897479789     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.03.014     Document Type: Article

References (62)

1. Mullard A. 2012 FDA drug approvals. Nat. Rev. Drug Discovery 2013, 12:87-90.
2. Lawrence S. Billion dollar babies-biotech drugs as blockbusters. Nat. Biotechnol. 2007, 25:380-382.
3. Schneider C.K., Vleminckx C., Gravanis I., Ehmann F., Trouvin J.H., Weise M., Thirstrup S. Setting the stage for biosimilar monoclonal antibodies. Nat. Biotechnol. 2012, 30:1179-1185.
4. Berkowitz S.A., Engen J.R., Mazzeo J.R., Jones G.B. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat. Rev. Drug Discovery 2012, 11:527-540.
5. Arrowsmith J. A decade of change. Nat. Rev. Drug Discovery 2012, 11:17-18.
6. Signore A., Annovazzi A., Chianelli M., Corsetti F., Van de Wiele C., Watherhouse R.N. Peptide radiopharmaceuticals for diagnosis and therapy. Eur. J. Nucl. Med. 2001, 28:1555-1565.
7. Khan I.U., Beck-Sickinger A.G. Targeted tumor diagnosis and therapy with peptide hormones as radiopharmaceuticals. Anticancer Agents Med. Chem. 2008, 8:186-199.
8. Okarvi S.M. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer. Cancer Treat. Rev. 2008, 34:13-26.
9. Wynendaele E., Bracke N., Stalmans S., Spiegeleer B.D. Development of peptide and protein based radiopharmaceuticals. Curr. Pharm. Des. 2013, (in press).
10. Cutler C.S., Hennkens H.M., Sisay N., Huclier-Markai S., Jurisson S.S. Radiometals for combined imaging and therapy. Chem. Rev. 2013, 113:858-883.
11. Buscombe J. Radiolabeled probes targeting G-protein-coupled receptors for personalized medicine. Curr. Pharm. Des. 2013, (in press).
12. Koch T.K., Berg B.O., Dearmond S.J., Gravina R.F. Creutzfeldt-Jakob disease in a young-adult with idiopathic hypopituitarism-possible relation to the administration of cadaveric human growth-hormone. N. Engl. J. Med. 1985, 313:731-733.
13. Walsh G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 2010, 28:917-924.
14. Dubois A., Gsteiger S., Balser S., Pigeolet E., Steimer J.L., Pillai G., Mentre F. Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling. Clin. Pharmacol. Ther. 2012, 91:234-242.
15. Heim H.K. Similar biological medicinal products currently licensed in the European Union-overview of non-clinical study programs. Biologicals 2011, 39:284-288.
16. Saenger P. Current status of biosimilar growth hormone. Int. J. Pediatr. Endocrinol. 2009, 2009:370329.
17. Jiang H.T., Wu S.L., Karger B.L., Hancock W.S. Mass spectrometric analysis of innovator, counterfeit, and follow-on recombinant human growth hormone. Biotechnol. Prog. 2009, 25:207-218.
18. Thevis M., Bredehoft M., Kohler M., Schanzer W. Mass spectrometry-based analysis of IGF-1 and hGH. Handb. Exp. Pharmacol. 2010, 201-207.
19. Bidlingmaier M., Strasburger C.J. Growth hormone. Handb. Exp. Pharmacol. 2010, 187-200.
20. Ehrnborg C., Bengtsson B.A., Rosen T. Growth hormone abuse. Baillieres Best Pract. Res. Clin. Endocrinol. Metab. 2000, 14:71-77.
21. Holt R.I.G., Erotokritou-Mulligan I., Sonksen P.H. The history of doping and growth hormone abuse in sport. Growth Horm. IGF Res. 2009, 19:320-326.
22. Courtheyn D., Le Bizec B., Brambilla G., De Brabander H.F., Cobbaert E., de Wiele A.V., Vercammen J., De Wasch K. Recent developments in the use and abuse of growth promoters. Anal. Chim. Acta 2002, 473:71-82.
23. Olshansky S.J., Perls T.T. New developments in the illegal provision of growth hormone for anti-aging and bodybuilding. JAMA 2008, 299:2792-2794.
24. Cunningham B.C., Wells J.A. Comparison of a structural and a functional epitope. J. Mol. Biol. 1993, 234:554-563.
25. Amit T., Hacham H., Daily O., Hertz P., Barkey R.J., Hochberg Z. The Hep G2 cell line in the study of growth hormone receptor/binding protein. Mol. Cell. Endocrinol. 1994, 101:29-36.
26. de Vos A.M., Ultsch M., Kossiakoff A.A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992, 255:306-312.
27. Poger D., Mark A.E. Turning the growth hormone receptor on: evidence that hormone binding induces subunit rotation. Proteins 2010, 78:1163-1174.
28. Bidosee M., Karry R., Weiss-Messer E., Barkey R.J. Regulation of growth hormone receptors in human prostate cancer cell lines. Mol. Cell. Endocrinol. 2009, 309:82-92.
29. Weiss-Messer E., Merom O., Adi A., Karry R., Bidosee M., Ber R., Kaploun A., Stein A., Barkey R.J. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Mol. Cell. Endocrinol. 2004, 220:109-123.
30. Gebre-Medhin M., Kindblom L.G., Wennbo H., Tornell J., Meis-Kindblom J.M. Growth hormone receptor is expressed in human breast cancer. Am. J. Pathol. 2001, 158:1217-1222.
31. Yang X.D., Liu F.K., Xu Z., Chen C., Li G., Wu X.Y., Li J.S. Growth hormone receptor expression in human colorectal cancer. Dig. Dis. Sci. 2004, 49:1493-1498.
32. Clayton P.E., Banerjee I., Murray P.G., Renehan A.G. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat. Rev. Endocrinol. 2011, 7:11-24.
33. Perry J.K., Liu D.X., Wu Z.S., Zhu T., Lobie P.E. Growth hormone and cancer: an update on progress. Curr. Opin. Endocrinol. Diabetes Obes. 2013, 20:307-313.
34. Maamra M., Finidori J., Von Laue S., Simon S., Justice S., Webster J., Dower S., Ross R. Studies with a growth hormone antagonist and dual-fluorescent confocal microscopy demonstrate that the full-length human growth hormone receptor, but not the truncated isoform, is very rapidly internalized independent of Jak2-Stat5 signaling. J. Biol. Chem. 1999, 274:14791-14798.
35. Brechbiel M.W. Bifunctional chelates for metal nuclides. Q. J. Nucl. Med. Mol. Imaging 2008, 52:166-173.
36. Price E.W., Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chem. Soc. Rev. 2013, (in press).
37. Haselberg R., Brinks V., Hawe A., de Jong G.J., Somsen G.W. Capillary electrophoresis-mass spectrometry using noncovalently coated capillaries for the analysis of biopharmaceuticals. Anal. Bioanal. Chem. 2011, 400:295-303.
38. Baker N.A., Sept D., Joseph S., Holst M.J., McCammon J.A. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc. Nat. Acad. Sci. U.S.A. 2001, 98:10037-10041.
39. Nielsen J.E., Vriend G. Optimizing the hydrogen-bond network in Poisson-Boltzmann equation-based pK(a) calculations. Proteins 2001, 43:403-412.
40. Bank R.E., Holst M. A new paradigm for parallel adaptive meshing algorithms. Siam J. Sci. Comput. 2000, 22:1411-1443.
41. Dolinsky T.J., Nielsen J.E., McCammon J.A., Baker N.A. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 2004, 32:W665-W667.
42. Dolinsky T.J., Czodrowski P., Li H., Nielsen J.E., Jensen J.H., Klebe G., Baker N.A. PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res. 2007, 35:W522-W525.
43. MacKerell A.D., Bashford D., Bellott M., Dunbrack R.L., Evanseck J.D., Field M.J., Fischer S., Gao J., Guo H., Ha S., Joseph-McCarthy D., Kuchnir L., Kuczera K., Lau F.T.K., Mattos C., Michnick S., Ngo T., Nguyen D.T., Prodhom B., Reiher W.E., Roux B., Schlenkrich M., Smith J.C., Stote R., Straub J., Watanabe M., Wiorkiewicz-Kuczera J., Yin D., Karplus M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 1998, 102:3586-3616.
44. Mackerell A.D., Feig M., Brooks C.L. Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J. Comput. Chem. 2004, 25:1400-1415.
45. Phillips J.C., Braun R., Wang W., Gumbart J., Tajkhorshid E., Villa E., Chipot C., Skeel R.D., Kale L., Schulten K. Scalable molecular dynamics with NAMD. J. Comput. Chem. 2005, 26:1781-1802.
46. Chantalat L., Jones N.D., Korber F., Navaza J., Pavlovsky A.G. The crystal-structure of wild-type growth-hormone at 2.5 Angstrom resolution. Protein Pept. Lett. 1995, 2:333-340.
47. Essmann U., Perera L., Berkowitz M.L., Darden T., Lee H., Pedersen L.G. A smooth particle mesh Ewald method. J. Chem. Phys. 1995, 103:8577-8593.
48. Clarke E.T., Martell A.E. Stabilities of the Fe(III), Ga(III) and In(III) chelates of N,N',N-triazacyclononanetriacetic acid. Inorg. Chim. Acta 1991, 181:273-280.
49. Manning M.C., Patel K., Borchardt R.T. Stability of protein pharmaceuticals. Pharm. Res. 1989, 6:903-918.
50. Zhang W.J., Luo X., Liu Y.L., Shao X.X., Wade J.D., Bathgate R.A.D., Guo Z.Y. Site-specific DOTA/europium-labeling of recombinant human relaxin-3 for receptor-ligand interaction studies. Amino Acids 2012, 43:983-992.
51. Loot A.E., van Buiten A., Roks A.J., Henning R.H. The suitability of iodinated Angiotensin-(1-7) peptides as pharmacological tools. J. Pharmacol. Toxicol. Methods 2005, 51:51-55.
52. Jeong J.M., Hong M.K., Chang Y.S., Lee Y.S., Kim Y.J., Cheon G.J., Lee D.S., Chung J.K., Lee M.C. Preparation of a promising angiogenesis PET imaging agent: Ga-68-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J. Nucl. Med. 2008, 49:830-836.
53. Li Z.B., Chen K., Chen X. Ga-68-labeled multimeric RGD peptides for microPET imaging of integrin alpha(V)beta(3) expression. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:1100-1108.
54. Staub A., Guillarme D., Schappler J., Veuthey J.L., Rudaz S. Intact protein analysis in the biopharmaceutical field. J. Pharm. Biomed. Anal. 2011, 55:810-822.
55. Haselberg R., de Jong G.J., Somsen G.W. Capillary electrophoresis-mass spectrometry for the analysis of intact proteins 2007-2010. Electrophoresis 2011, 32:66-82.
56. Fekete S., Veuthey J.L., Guillarme D. New trends in reversed-phase liquid chromatographic separations of therapeutic peptides and proteins: theory and applications. J. Pharm. Biomed. Anal. 2012, 69:9-27.
57. Garcia B.A. What does the future hold for top down mass spectrometry?. J. Am. Soc. Mass Spectrom. 2010, 21:193-202.
58. European Directorate for the Quality of Medicines and HealthCare European Pharmacopoeia 8.0 2014, Council of Europe, Strassbourg.
59. Haselberg R., de Jong G.J., Somsen G.W. Capillary electrophoresis-mass spectrometry for the analysis of intact proteins. J. Chromatogr. A 2007, 1159:81-109.
60. Olsen J.V., Ong S.E., Mann M. Trypsin cleaves exclusively C-terminal to arginine and lysine residues. Mol. Cell. Proteomics 2004, 3:608-614.
61. Wilkins M.R., Gasteiger E., Bairoch A., Sanchez J.C., Williams K.L., Appel R.D., Hochstrasser D.F. Protein identification and analysis tools in the ExPASy server. Methods Mol. Biol. 1999, 112:531-552.
62. Sakal E., Gertler A., Shechter Y. Biological-activity of a fluorescein human growth-hormone derivative prepared by specific covalent labeling of Lysine-70. Biochemistry (Mosc.) 1991, 30:8899-8904.